For research use only. Not for therapeutic Use.
Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research[1].
Epoetin beta (rhEPO) (1000 IU/kg; s.c.; three times per week over 14 days) prevents anaemia and enhances the radiosensitivity of solid growing DS-sarcomas[2].
| Catalog Number | M022217 |
| CAS Number | 122312-54-3 |
| Purity | ≥95% |
| Reference | [1]. Cheer SM, et al. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs. 2004;64(3):323-46. [2]. Thews O, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 1998 Sep;78(6):752-6. |
